La Jolla Pharmaceutical (LJPC) Tops Q1 EPS by 9c

La Jolla Pharmaceutical (NASDAQ: LJPC) reported Q1 EPS of ($0.90), $0.09 better than the analyst estimate of ($0.99).

As of June 30, 2016, La Jolla had $100.6 million in cash and cash equivalents, compared to $126.5 million as of December 31, 2015. The decrease in cash and cash equivalents was primarily due to net cash used for operating activities. Based on current operating plans and projections, La Jolla believes that its current cash and cash equivalents are sufficient to fund operations into 2018.

For earnings history and earnings-related data on La Jolla Pharmaceutical (LJPC) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Autoliv (ALV) Tops Q1 EPS by 14c
• Carter's (CRI) Tops Q1 EPS by 29c